Reslizumab
From Wikipedia, the free encyclopedia
Reslizumab
|
|
|
|
Source | Human |
Target | ? |
Identifiers | |
CAS number | ? |
ATC code | ? |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Reslizumab is a humanized monoclonal antibody which it's used as an immunosuppressive drug.
[edit] External link
Abatacept, Abetimus, Adalimumab, Afelimomab, Anakinra, Alefacept, Antilymphocyte immunoglobulin (horse), Antithymocyte immunoglobulin (rabbit), Aselizumab, Atlizumab, Atorolimumab, Azathioprine, Basiliximab, Belatacept, Belimumab, Bertilimumab, Cedelizumab, Ciclosporin, Citilimumab, Clenoliximab, Daclizumab, Difirolimus, Dofosirolimus, Dorlimomab aritox, Eculizumab, Efalizumab, Elsilimomab, Enlimomab, Enlimomab pegol, Erlizumab, Etanercept, Everolimus, Faralimomab, Fontolizumab, Galiximab, Gavilimomab, Gifosirolimus, Golimumab, Gomiliximab, Gusperimus, Infliximab, Inolimomab, Ipilimumab, Keliximab, Leflunomide, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Methotrexate, Morolimumab, Muromonab-CD3, Mycophenolic acid, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Pascolizumab, Pexelizumab, Pimecrolimus, Reslizumab, Rovelizumab, Ruplizumab, Safosirolimus, Siplizumab, Sirolimus, Tacrolimus, Talizumab, Telimomab aritox, Teneliximab, Thalidomide, Ticilimumab, Tilolizumab, Tocilizumab, Toralizumab, Torolimus, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox
Alemtuzumab, Apolizumab, Aselizumab, Atlizumab, Bapineuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Cedelizumab, Certolizumab pegol, Cidfusituzumab, Cidtuzumab, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Felvizumab, Fontolizumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Mepolizumab, Motavizumab, Motovizumab, Natalizumab, Nimotuzumab, Nolovizumab, Numavizumab, Ocrelizumab, Omalizumab, Palivizumab, Pascolizumab, Pecfusituzumab, Pectuzumab, Pertuzumab, Pexelizumab, Ralivizumab, Ranibizumab, Reslivizumab, Reslizumab, Resyvizumab, Rovelizumab, Ruplizumab, Sibrotuzumab, Siplizumab, Sontuzumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tefibazumab, Tocilizumab, Toralizumab, Trastuzumab, Tucotuzumab celmoleukin, Tucusituzumab, Umavizumab, Urtoxazumab, Visilizumab